| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 334.496 | 353.625 | 379.709 | 423.843 | 451.564 | 20.297 | 21.256 | 18.560 | 23.875 | 28.587 |
| Total Income - EUR | 334.955 | 358.005 | 408.902 | 424.399 | 768.619 | 20.341 | 24.878 | 18.712 | 23.908 | 37.493 |
| Total Expenses - EUR | 318.889 | 348.815 | 379.196 | 404.299 | 404.287 | 29.648 | 15.184 | 17.474 | 17.607 | 34.196 |
| Gross Profit/Loss - EUR | 16.066 | 9.190 | 29.706 | 20.100 | 364.332 | -9.307 | 9.694 | 1.238 | 6.301 | 3.296 |
| Net Profit/Loss - EUR | 13.496 | 7.447 | 25.154 | 16.091 | 356.646 | -9.450 | 9.557 | 1.056 | 6.067 | 2.962 |
| Employees | 8 | 8 | 8 | 9 | 8 | 1 | 1 | 1 | 1 | 1 |
Check the financial reports for the company - Galenus Pharm Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 44.000 | 35.396 | 12.025 | 6.162 | 2.523 | 0 | 0 | 0 | 425 | 455 |
| Current Assets | 95.729 | 92.330 | 90.658 | 125.497 | 426.120 | 368.063 | 229.675 | 207.935 | 213.837 | 218.240 |
| Inventories | 42.235 | 44.103 | 34.257 | 40.396 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 29.226 | 17.720 | 42.690 | 63.749 | 117.223 | 3.671 | 4.772 | 1.219 | 1.967 | 2.050 |
| Cash | 24.268 | 30.508 | 13.711 | 21.352 | 308.897 | 364.392 | 224.903 | 206.716 | 211.870 | 216.190 |
| Shareholders Funds | 31.445 | 8.677 | 26.363 | 41.971 | 386.784 | 359.706 | 227.867 | 207.153 | 212.592 | 214.366 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 108.284 | 119.049 | 76.395 | 89.752 | 41.894 | 8.366 | 1.808 | 782 | 1.669 | 4.329 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "6820 - 6820" | |||||||||
| CAEN Financial Year |
6820
|
|||||||||
Comments - Galenus Pharm Srl